Company: INKT
Filing Date: 2025-03-18
Form Type: 10-K
Source: 0000950170-25-041379
Chunk: 158

Company: MiNK Therapeutics, Inc.
Filing Date: 2025-03-18
Form: 10-K
Item: Item 1B
Chunk 158
---
 Group Personal Pension Plan in the United Kingdom (the “Plans”) for all eligible employees, as defined in the Plans. Participants may contribute a portion of their compensation, subject to a maximum annual amount, as established by the applicable taxing authority. Each participant is fully vested in his or her contributions and related earnings and losses. For the years ended December 31, 2024 and 2023, the Company expensed $156,000 and $172,000, respectively, related to the discretionary contribution to the Plans. 

(14) Segments MiNK is managed and operated as one business segment. The Company does not operate separate lines of business with respect to any of its product candidates or geographic locations. MiNK's single reportable segment is focused on the discovery, development and manufacturing of allogeneic, off-the-shelf, iNKT cell therapies to treat cancer and other immune-mediated diseases.MiNK's CEO serves as its Chief Operating Decision Maker (“CODM”) and is responsible for reviewing company performance and making decisions regarding resource allocation. The Company's CODM evaluates company performance based on net loss, as included in the Consolidated Statements of Operations and Comprehensive Loss, ensuring resource allocation decisions support company goals. The measure of segment assets is total assets, as included in the Consolidated Balance Sheets. Refer to the consolidated financial statements for other financial information regarding the Company's single reportable segment.The following table presents selected financial information related to the Company's single reportable segment for the years ended December 31, 2024 and 2023 (in thousands):

        Year Ended December 31,

        2024

        2023

        Operating expenses:

        External expenses
         
        $
        (2,452
        )
         
        $
        (9,885
        )

        Payroll related expenses

        (5,217
        )

        (8,211
        )

        Other operating expenses

        (3,619
        )

        (4,825
        )

        Operating loss

        (11,288
        )

        (22,921
        )

        Other income (expense):

        Interest expense

        (93
        )

        (28
        )

        Interest income

        265

        491

        Other income

        331

        —

        Net loss
         
        $
        (10,785
        )
         
        $
        (22,458
        )
       
      In the table above, “Other operating